Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMHQKN6)

• Drug Name: CART-19 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Phase 2	[1]
Chronic lymphocytic leukaemia	2A82.0	Phase 2	[1]
Non-hodgkin lymphoma	2B33.5	Phase 2	[2]
B-cell chronic lymphocytic leukaemia	2A82.00	Phase 1	[1]
B-cell lymphoma	2A86	Phase 1	[3]
Diffuse large B-cell lymphoma	2A81	Phase 1	[1]
Follicular lymphoma	2A80	Phase 1	[1]
Haematopoietic/lymphoid cancer	2B33.5	Phase 1	[1]
leukaemia	2A60-2B33	Phase 1	[3]
Mantle cell lymphoma	2A85.5	Phase 1	[1]
Prolymphocytic leukaemia	2A82.1	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMHQKN6

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	CAR-T-Cell-Therapy	[1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
B-lymphocyte surface antigen B4 (CD19)	DTT	CD19	5.758	6.211	6.083	5.396

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Acute lymphoblastic leukaemia
• ICD Disease Classification: 2A85

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
B-lymphocyte surface antigen B4 (CD19)	DTT	CD19	2.33E-24	-1.06	-1.33

References

• [1] ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
• [2] ClinicalTrials.gov (NCT02030834) Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
• [3] ClinicalTrials.gov (NCT01626495) Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma